Pharmaceutical giant Merck, based in Kenilworth, NJ announced that its grazoprevir/elbasvir has received two new Breakthrough Therapy designations (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic hepatitis C virus (HCV) genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis.  Grazprevir/elbasvir is an investigational once-daily single tablet combo for the treatment of chronic HCV infection.  Grazoprevir is a protease inhibitor while grazoprevir is a replication complex inhibitor.  The phase II and III clinical data are expected to be presented at The International Liver Congress later this month. HCV infects liver and causes hepatitis C.  According to WHO, 130-150 million people globally have chronic hepatitis C infection and this condition could result in serious, life-long illness.  Current antiviral treatment has only 50-90% success rate and there is an unmet medical need.

Original Article:


  1. I have relapsed on sovaldi-olysio and another relapse with 24 weeks of Harvoni.I am geno 1a stage 4 but still in good shape.I wasn’t allowed to participate in two trials with grazoprevir/elbasvir.The first because it was for people who have only done Harvoni and relapsed and the other was just for non cirrhotics.I do want to save my liver but I am being blocked from every angle.Can I purchase these meds on my own? I need these meds and my family needs me.